|
Volumn 8, Issue 3, 2004, Pages 255-258
|
Ocular angiogenesis: Translating preclinical indications to successful clinical development
|
Author keywords
Age related macular degeneration (AMD); Antiangiogenesis; Choroidal neovascularisation (CNV); Gene therapy; Ocular angiogenesis; RNA (siRNA); Small interfering; Vascular endothelial growth factor (VEGF)
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANGIOSTATIN;
ENDOSTATIN;
F 200;
GANCICLOVIR;
PEGAPTANIB;
PIGMENT EPITHELIUM DERIVED FACTOR;
RANIBIZUMAB;
SMALL INTERFERING RNA;
STEROID;
UNCLASSIFIED DRUG;
VASCULOTROPIN;
VEGF TRAP;
VERY LATE ACTIVATION ANTIGEN 5;
VERY LATE ACTIVATION ANTIGEN 5 ANTIBODY;
BLINDNESS;
CLINICAL TRIAL;
CONFERENCE PAPER;
DIABETIC RETINOPATHY;
DRUG DELIVERY SYSTEM;
DRUG DESIGN;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG SCREENING;
DRUG TARGETING;
GENE THERAPY;
HUMAN;
LONG TERM CARE;
NEOVASCULARIZATION (PATHOLOGY);
NONHUMAN;
RECEPTOR BLOCKING;
RETINA MACULA AGE RELATED DEGENERATION;
SOCIOECONOMICS;
SUBRETINAL NEOVASCULARIZATION;
TREATMENT OUTCOME;
WESTERN HEMISPHERE;
ANIMALS;
DIABETIC RETINOPATHY;
DRUG DELIVERY SYSTEMS;
HUMANS;
MACULAR DEGENERATION;
RETINAL NEOVASCULARIZATION;
|
EID: 3042715231
PISSN: 14728222
EISSN: None
Source Type: Journal
DOI: 10.1517/14728222.8.3.255 Document Type: Conference Paper |
Times cited : (15)
|
References (7)
|